PLRX
Income statement / Annual
Last year (2024), Pliant Therapeutics, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Pliant Therapeutics, Inc.'s net income was -$210.30 M.
See Pliant Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$1.58 M |
$9.69 M |
$7.57 M |
$41.82 M |
$57.05 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$666.00 K
|
$0.00
|
| Gross Profit |
$0.00
|
$1.58 M
|
$9.69 M
|
$7.57 M
|
$41.82 M
|
$57.05 M
|
-$666.00 K
|
$0.00
|
| Gross Profit Ratio |
0
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
| Research and Development Expenses |
$169.31 M
|
$127.80 M
|
$96.94 M
|
$77.55 M
|
$66.19 M
|
$47.35 M
|
$24.42 M
|
$14.53 M
|
| General & Administrative Expenses |
$59.06 M
|
$57.93 M
|
$39.95 M
|
$27.56 M
|
$17.27 M
|
$10.93 M
|
$6.50 M
|
$3.82 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$59.06 M
|
$57.93 M
|
$39.95 M
|
$27.56 M
|
$17.27 M
|
$10.93 M
|
$6.50 M
|
$3.82 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$49.00 K
|
$0.00
|
| Operating Expenses |
$228.37 M
|
$185.73 M
|
$136.89 M
|
$105.11 M
|
$83.46 M
|
$58.28 M
|
$30.92 M
|
$18.35 M
|
| Cost And Expenses |
$228.37 M
|
$185.73 M
|
$136.89 M
|
$105.11 M
|
$83.46 M
|
$58.28 M
|
$30.92 M
|
$18.35 M
|
| Interest Income |
$21.09 M
|
$24.08 M
|
$4.67 M
|
$272.00 K
|
$478.00 K
|
$816.00 K
|
$688.00 K
|
$16.00 K
|
| Interest Expense |
$3.02 M
|
$1.27 M
|
$791.00 K
|
$0.00
|
$366.00 K
|
$216.00 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$2.13 M
|
$1.84 M
|
$3.68 M
|
$1.54 M
|
$1.31 M
|
$1.11 M
|
$666.00 K
|
$292.00 K
|
| EBITDA |
-$205.16 M |
-$158.23 M |
-$118.85 M |
-$95.73 M |
-$40.34 M |
-$118.00 K |
-$30.25 M |
-$18.06 M |
| EBITDA Ratio |
0
|
-100.14
|
-12.27
|
-12.64
|
-0.96
|
-0
|
0
|
0
|
| Operating Income Ratio |
0
|
-116.55
|
-13.13
|
-12.88
|
-1
|
-0.02
|
0
|
0
|
| Total Other Income/Expenses Net |
$18.06 M
|
$22.81 M
|
$3.88 M
|
$272.00 K
|
$112.00 K
|
$600.00 K
|
$639.00 K
|
$16.00 K
|
| Income Before Tax |
-$210.30 M
|
-$161.34 M
|
-$123.32 M
|
-$97.26 M
|
-$41.53 M
|
-$631.00 K
|
-$30.28 M
|
-$18.33 M
|
| Income Before Tax Ratio |
0
|
-102.11
|
-12.73
|
-12.85
|
-0.99
|
-0.01
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$210.30 M
|
-$161.34 M
|
-$123.32 M
|
-$97.26 M
|
-$41.53 M
|
-$631.00 K
|
-$30.28 M
|
-$20.62 M
|
| Net Income Ratio |
0
|
-102.11
|
-12.73
|
-12.85
|
-0.99
|
-0.01
|
0
|
0
|
| EPS |
-3.47 |
-2.75 |
-2.94 |
-2.71 |
-1.17 |
0.0052 |
-1.83 |
-25.67 |
| EPS Diluted |
-3.47 |
-2.75 |
-2.94 |
-2.71 |
-1.17 |
0.0052 |
-1.83 |
-25.67 |
| Weighted Average Shares Out |
$60.54 M
|
$58.72 M
|
$42.02 M
|
$35.85 M
|
$35.55 M
|
$35.55 M
|
$16.51 M
|
$803.50 K
|
| Weighted Average Shares Out Diluted |
$60.54 M
|
$58.72 M
|
$42.02 M
|
$35.85 M
|
$35.55 M
|
$35.55 M
|
$16.51 M
|
$803.50 K
|
| Link |
|
|
|
|
|
|
|
|
